诺诚健华(09969.HK) 公布,奥布替尼(宜诺凯,HIBRUKA)已获澳洲药品管理局(TGA)批准,用于治疗复发或难治性套细胞淋巴瘤(r/r MCL)成年患者。(jl/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-05-27 16:25。)AASTOCKS新闻
Source Link诺诚健华(09969.HK) 公布,奥布替尼(宜诺凯,HIBRUKA)已获澳洲药品管理局(TGA)批准,用于治疗复发或难治性套细胞淋巴瘤(r/r MCL)成年患者。(jl/a)(港股报价延迟最少十五分钟。沽空资料截至 2026-05-27 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.